Mar 14 |
IN8bio GAAP EPS of -$0.22
|
Mar 14 |
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
|
Mar 5 |
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
|
Feb 26 |
IN8bio to Present at Upcoming Investor Conferences
|
Feb 14 |
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
|
Jan 12 |
IN8bio files to sell 42.7M shares for holders
|
Jan 4 |
In8bio stock jumps 11% following clinical update
|
Jan 4 |
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
|
Dec 13 |
Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
|
Dec 11 |
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
|